Health Management Case Study: Hoffmann-La Roche

Americans have access to and benefit from one of the most technologically advanced pharmaceutical systems in the world. However, this system is also very strict and tedious. The system this paper will evaluate is the United States Food and Drug Administration (FDA), more specifically, the FDA’s Center for Drug Evaluation and Research (CDER). Although, having access to this system can be frustrating to those that are in the pharmaceutical development industry or those that have illnesses and need the best drugs available in order to cope with their symptoms.

SM moved to Arlington, Texas in October of 2016 from North Carolina after having difficulty living alone without support. He has had medication from his previous primary care provider in North Carolina. He recently attempted to go to the Dallas VA and had difficulty making an appointment in order to refill his medications. He reported that his current plan is to get an appointment with TRICARE for medication management. According to his report, his only psychotropic medication is currently Wellbutrin. While still in North Carolina SM has been taking medication which he received from his primary care provider in North Carolina. SM was also seeing a psychologist once a week, but then abruptly stopped going to him and has not reconnected with

Firstly, our current pharmacare system does not provide access to individuals who need prescription drugs and are unable to afford it (Morgan, Daw and Law 2014). Prescription drugs are inputs into the broader health care system. As such, if prescription drugs are taken on time, this allows the healthcare system to meet patient health needs (Morgan, Daw and Law 2014). Secondly, our current pharmacare system does not ensure that the financial costs associated with necessary medicine are equally distributed (Morgan, Daw and Law 2014). Unequal distribution of the costs of necessary medicine can further drive income inequality (Morgan, Daw and Law 2014). Also, employers are under no obligation to continue providing private insurance for their employees

With all the health insurance options available, it’s hard to know which plan is right for your family. You want a plan that’s affordable, flexible, and provides comprehensive coverage for you and your loved ones. USHealth Group, with its headquarters in Fort Worth, TX, can help customize a plan that will meet your family’s unique needs.

The company mission statement indicates that it envisions becoming a principal pharmaceutical manufacturing corporation with a special dedication to advance innovation in medicine with the

The customer indicated that she was diagnosed with Schizoaffective Disorder and Generalized Anxiety Disorder. Ms. Knight has been prescribed Invega 9 MG (use as antipsychotic) and Effexor 3.5 MG (use to treat symptoms associated with anxiety and depression) by Dr. Miriam Ajo, MD at SalusCare. Medication management services are provided by the mentioned institution every three to four months. The customer was hospitalized in September, 2016 because she had a manic episode. She was Baker Act in 2004 and 2007. At the time of the evaluation she denied the presence of suicidal ideation, intent or plans.

Every organization has the opportunity to maximize their return by how they strategically fit themselves in their respective market place and by how they manage the internal assets to maximize their utilization. InVentiv Health is a Contract Research Organization (CRO) that provides support for commercialization, preclinical research, clinical research and clinical trials management within the pharmaceutical industry. InVentiv Health specializes in clinical trial services and offers their clients the expertise of moving an asset, drug or device through the FDA approval process, from conception to

The clinical research market is a very vast and ever changing market. There are continuous evolutions taking place and there are always new products coming into market everyday. Though it takes many years for a drug to come into market there is a continuous research going on. There are advancements taking place continuously in this industry, which is not possible without the main players and stakeholders within the industry. These stake holders range in a broad area which include site management organizations, researchers, developers, regulators, participants, government agencies etc.

The industry is impacted by financial challenges for drug development and diagnostics (2016). The cost of drug development may rise due to more complex procedures, i.e. biomarker analysis (2016). The underdevelopment of pharmaceutical regulations (2016), relating to personalised medicine, may threaten the introduction of these treatments and diagnostics in healthcare. The pharmaceutical industry is also faced with scientific challenges in the development of personalised medicine, many of the sciences used to develop drugs and diagnostic techniques are emerging and not yet fully developed, molecular profiling for example (2016) leading to the choosing of an incorrect biomarker for a disease can prove extremely costly and timely for drug development programs as explained by A. Ayers (2016). The handling of more complex data may result in the need for new, more powerful computing and statistical methods (2016).

Governments must not, however, accept uncritically the claims from the industry that any constraint on profits will threaten truly valuable innovation. However, new drug developments that lead to improvements in health outcomes are valuable to society and truly innovative drugs should be appropriately rewarded. (Mossialos)

At Johnson & Johnson, the depth and breadth of global operations demands an extensive division organizational structure. In a division organizational structure the central corporate office governs the divisions of the company, but the operating segments have

In summary of the Pfizer case study, the organization realized executives and key employees were spending 20-40% of their time on support work rather than knowledge work. In response, the company started a “magic button” process. When an employee would like to pass off the tasks that are monotonous or lack luster they can press the “magic button”. The tasks are assigned to individuals of an outside organization for completion. The result is an increase of employee productivity.

Unlike Gilead that has only one product in its Oncology line, Bristol-Myers Squibb presently have four different drugs namely: Erbitux –an epidermal growth factor receptor (EGFR) antagonist for the treatment of Head & Neck cancer and Colorectal cancer,(2) Opdivo (nivolumab) for the treatment of unresectable or metastic melanoma and lungs cancer, (3) Syrcel( dasatinb) for the treatment of newly diagnosed adult with Philadelphia chromosome –positive (ph+) chronic myeloid leukemia and (4) Yervoy (ipilimumob) for the treatment of melanoma a type of skin cancer that spread and as such cannot be remove by surgery. Like Seattle Genetics, the company products use either Antibody-drug Conjugate (ADC) though in a different version by linking potent cytotoxic to monoclonal antibodies targeted to specific tumor cells or immune-oncology, an innovative technology that unlocks the body own immune system to fight against cancerous cells. It also expanded its focus to Nolch inhibitor (used in blocking powerful pathway that promotes tumor cell survival for certain other types of cancer. (Bristol-Myer Squibb, 2014) Because the technology is similar but used differently, BMS would be considered a close competitor who currently has the advantage of having four targeted specific drugs and 12 other oncology and immune-oncology in various trial phases.

Bayer AG is fully committed to expanding its business operations through pharmaceuticals, consumer health, and crop science. Bayer AG understands that in order for the company to successfully expand its Pharmaceuticals department they must properly invest in research, development, and marketing of innovative medicinal products. In addition, Bayer AG is developing clinical programs, which will enable the company to provide various of its products to a greater number of people. Bayer AG ability to identify areas in medicine that remain untapped is crucial to the firm’s long term sustainability. For example, Bayer AG has identified the fields of cardiology, oncology, gynecology, and

The research and development of the pharmaceutical industry is very important as the industry relies on it to develop new products to maintain and sustain the growth of the industry (ALRC 2014). According to the Australian Government Law Reform Commission, every year, the total spending in research and development in pharmaceutical industry, which includes drug discovery, pre-clinical testing and clinical trials on drugs is around $300 million (ALRC 2014). Mergers and acquisitions are intensifying in the global pharmaceutical industry, especially over the last 10 years. With factors like exorbitant research and development costs, the relatively shorter product life cycles, and the rarity of discovering a new life-changing drug acting as catalysts, leading pharmaceutical companies now have more cause to step out and look for external collaboration. This results in an increasing number of smaller biotechnology companies merging with bigger pharmaceutical companies (The